AMGEN NEUPOGEN APPROVED FOR BONE MARROW TRANSPLANT
Executive Summary
AMGEN NEUPOGEN APPROVED FOR BONE MARROW TRANSPLANT use by FDA June 20, the second indication for the granulocyte colony stimulating factor. New labeling for Neupogen (filgrastim) states that it is indicated to "reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g. febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation." Amgen's PLA for the indication was filed in July 1992.